Epic Patient Portal Adoption Among Vulnerable Oncology Patients in the Era of Oral Anticancer Medications
JCO Oncology Practice · 2026
DOI: 10.1200/op-25-00630 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2026. Verfasst von Yenong Cao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Boston Medical Center, Boston, MA. Hauptthemen laut MEDLINE: Patient Portals, Antineoplastic Agents, Vulnerable Populations, Neoplasms. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
PURPOSE We characterized patient portal signup in the electronic health record and messaging use among vulnerable oncology patients identified as having newly initiated an oral anticancer medication (OAM), evaluating opportunities to improve patient portal adoption and thus patient communication with their oncology care teams. PATIENTS AND METHODS We conducted a retrospective analysis of patients who newly initiated an OAM at Tufts Medical Center between October 1, 2022, and March 31, 2024. Vulnerability was defined as meeting at least one of the following criteria: age ≥75 years; non-English language; or subsidized insurance (Medicaid only or Medicare with Medicaid as a secondary insurance). Active portal use was defined as having at least one message in the portal; meaningful use was defined as patient-provider bidirectional messaging. Portal messaging proxy use was determined by message content screening. Fisher's exact test evaluated the impact of vulnerability on portal signup rate. Logistic regression was performed to identify factors associated with portal signup and meaningful use. RESULTS Among the study population (N = 280), 56% met the criteria of vulnerability. Although the overall portal signup rate was 74%, it was 64% among vulnerable patients and 87% in nonvulnerable patients ( P < .0001). Non-English language was associated with lower rate of portal signup ( P < .0001), but none of the vulnerable characteristics were associated with decreased meaningful use. Messaging by proxy was used by 17% of vulnerable versus 2.8% of nonvulnerable patients who signed up for portal. Among patients who signed up, 31% used the portal to communicate about OAM. CONCLUSION Although patient portal signup was lower among vulnerable patients, once adopted, vulnerable patients demonstrated comparable meaningful use and greater proxy engagement. Fostering patient portal adoption requires a targeted approach with patient navigation and patient proxy engagement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Boston Medical Center, Boston, MA.
- Boston University Chobanian & Avedisian School of Medicine, Boston, MA.
- Tufts Medical Center, Boston, MA.
- Duke University Health System, Durham, NC.
- Tufts University School of Medicine, Boston, MA.
ORCID-Profile: Yenong Cao, Angie Mae Rodday, Susan K Parsons
Zitieren
APA
Cao, Y., Baiyee, M. N. B., Ching, J., Murphy-Banks, R., Wang, F. Q., Maloney, A., Rodday, A. M., & Parsons, S. K. (2026). Epic Patient Portal Adoption Among Vulnerable Oncology Patients in the Era of Oral Anticancer Medications. JCO Oncology Practice. https://doi.org/10.1200/op-25-00630
Vancouver
Cao Y, Baiyee MNB, Ching J, Murphy-Banks R, Wang FQ, Maloney A, et al. Epic Patient Portal Adoption Among Vulnerable Oncology Patients in the Era of Oral Anticancer Medications. JCO Oncology Practice. 2026. doi:10.1200/op-25-00630
BibTeX
@article{Cao2026,
author = {Cao, Yenong and Baiyee, Marie Noelle Bate and Ching, Johnson and Murphy-Banks, Rachel and Wang, Feng Qing and Maloney, Antonia and Rodday, Angie Mae and Parsons, Susan K},
title = {Epic Patient Portal Adoption Among Vulnerable Oncology Patients in the Era of Oral Anticancer Medications},
journal = {JCO Oncology Practice},
year = {2026},
doi = {10.1200/op-25-00630}
}
EUVIMED